country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-108829A

Copy Link Print Information

Biologically Validated

Abatacept (powder)

(Synonyms: CTLA4lg (powder); BMS-188667 (powder); Orencia)

2 Cited Publications

Avis client

Based on 2 publication(s) in Google Scholar

Abatacept (CTLA4lg; BMS-188667) powder is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept powder is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.01%
CAS No.: 332348-12-6
Masse moléculaire:84.4 kDa

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Abatacept (powder) Chemical Structure

CAS No.: 332348-12-6

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Publications Citing Use of MedChemExpress (MCE) Abatacept (powder)

Customer Validation & Images

In Vivo Efficacy Study

In Vivo Efficacy Study
In Vivo Efficacy Study
In Vivo Efficacy Study

Activité biologique
- Description
- Species Reactivity
- In Vivo
- Target
- Conjugated
- Reconsititution
- Format
- Verified Bioactivity
Chemical Information
Publications (2)
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Species Reactivity

Human

In Vivo

Abatacept (powder) reduces paw edema, and the SC Multiple-dose group shows significantly greater (t_obs = 2.50) paw edema reduction compared with the IV dose group^[2].
Abatacept (powder) exhibits linear PK across the studied doses. The NCA clearance (CL) is 20.8 mL/day/kg, volume (V_ss) is 146 mL/kg, and bioavailability (F) of the SC dose dosing is 57.7%^[2].
Abatacept (powder) (oral; 10 mg/kg; every 2 days) reduces the proportion of activated T cells (CD44highCD62L–) and inhibits the up-regulation of ICOS and CD71 in homozygous DO11.10 RAG-2^–/–BALB/c (H-2d/d) mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male Lewis rats (6-9 weeks old) with weights of 150-175 g^[2]
Dosage:

10 mg/kg (IV), 20 mg/kg (SC single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29
Administration:

IV or SC
Result:

Reduced paw edema, and the SC Multiple-dose group showed significantly greater (t_obs = 2.50) paw edema reduction compared with the IV dose group.

Animal Model:

Male Lewis rats (6-9 weeks old) with weights of 150-175 g^[2]
Dosage:

10 mg/kg (IV), 20 mg/kg (SC single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29
Administration:

IV or SC
Result:

Reduced paw edema, and the SC Multiple-dose group showed significantly greater (t_obs = 2.50) paw edema reduction compared with the IV dose group.

Target

CD80 & CD86

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

[CTLA4 (cytotoxic T-lymphocyte-associated protein 4, CD152)]2-IGHG1 Fc (Fragment constant)

Verified Bioactivity

Flow cytometry analysis of CD80 overexpression CHOK1 cells labelling CD80 with Abatacept at 20nM (Red). Goat anti human IgG Fc (Alexa Fluor488) was used as the secondary antibody at 1/1000 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).

Chemical Information

CAS No. 332348-12-6
Appearance Solid
Masse moléculaire 84.4 kDa
Color White to off-white
SMILES

[Abatacept (powder)]
Synonyms

CTLA4lg (powder); BMS-188667 (powder); Orencia
Formulation

Please refer to the lot-specific COA for specific buffer information.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (2)

All In Vivo Efficacy Study

Sort by:

Journal Impact Factor

Cell Rep

Trained immunity is regulated by T cell-induced CD40-TRAF6 signaling. [Abstract]

2024 Aug 22;43(9):114664. PMID: 39178113

Abatacept (powder) purchased from MedChemExpress. Usage Cited in: Cell Rep. 2024 Aug 22;43(9):114664. [Abstract]

CTLA4-Ig (0.25 mg; ip). Kaplan-Meier curve with log-rank test for graft survival.

Abatacept (powder) purchased from MedChemExpress. Usage Cited in: Cell Rep. 2024 Aug 22;43(9):114664. [Abstract]

CTLA4-Ig (0.25 mg; ip). Leukocytes infiltrated in native hearts and allografts of CTLA4-Ig plus CD40-TRAF6i-NB-treated mice 100 days post-transplantation.

Abatacept (powder) purchased from MedChemExpress. Usage Cited in: Cell Rep. 2024 Aug 22;43(9):114664. [Abstract]

CTLA4-Ig (0.25 mg; ip). Immune cell subsets in allografts of CTLA4-Ig plus CD40-TRAF6i-NB-treated recipient mice 100 days post-transplantation.
SSRN

2026 Apr 24.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (261 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

Références

[1]. Kiykim A, et al. Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency. J Allergy Clin Immunol Pract. 2019 Jun 22. [Content Brief]

[2]. Lon HK, et al. Modeling pharmacokinetics/pharmacodynamics of abatacept and disease progression in collagen-induced arthritic rats: a population approach. J Pharmacokinet Pharmacodyn. 2013 Dec;40(6):701-12. [Content Brief]

[3]. Patakas A, et al. Abatacept Inhibition of T Cell Priming in Mice by Induction of a Unique Transcriptional Profile That Reduces Their Ability to Activate Antigen-Presenting Cells. Arthritis Rheumatol. 2016 Mar;68(3):627-38. [Content Brief]

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

Abatacept (powder)

2 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

MOQ

Minimum order quantity

100 mg

Obtenir un devis En stock

Other size

Obtenir un devis

Amount: USD 0.00

Activité biologique
- Description
- Species Reactivity
- In Vivo
- Target
- Conjugated
- Reconsititution
- Format
- Biological Activity
Chemical Information
Publications (2)
Pureté et documentation
Références

1/16

[CTLA4 (cytotoxic T-lymphocyte-associated protein 4, CD152)]2-IGHG1 Fc (Fragment constant)
1/16

Flow cytometry analysis of CD80 overexpression CHOK1 cells labelling CD80 with Abatacept at 20nM (Red). Goat anti human IgG Fc (Alexa Fluor488) was used as the secondary antibody at 1/1000 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).
1/16

Abatacept (powder) purchased from MedChemExpress. Usage Cited in: Cell Rep. 2024 Aug 22;43(9):114664. [Abstract]

Customer Validation
CTLA4-Ig (0.25 mg; ip). Kaplan-Meier curve with log-rank test for graft survival.
1/16

Abatacept (powder) purchased from MedChemExpress. Usage Cited in: Cell Rep. 2024 Aug 22;43(9):114664. [Abstract]

Customer Validation
CTLA4-Ig (0.25 mg; ip). Leukocytes infiltrated in native hearts and allografts of CTLA4-Ig plus CD40-TRAF6i-NB-treated mice 100 days post-transplantation.
1/16

Abatacept (powder) purchased from MedChemExpress. Usage Cited in: Cell Rep. 2024 Aug 22;43(9):114664. [Abstract]

Customer Validation
CTLA4-Ig (0.25 mg; ip). Immune cell subsets in allografts of CTLA4-Ig plus CD40-TRAF6i-NB-treated recipient mice 100 days post-transplantation.
1/16

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Abatacept (powder)

Antibody Inhibitor Library

Publications Citing Use of MedChemExpress (MCE) Abatacept (powder)

Activité biologique

Chemical Information

Publications (2)

Pureté et documentation

Références

Calculators

Help & FAQs

Abatacept (powder) Related Classifications

HY-108829A Related Classifications